StockNews.AI
NMRA
StockNews.AI
175 days

Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA

1. NMRA faces a class-action lawsuit over alleged trial misrepresentation. 2. Alleged trial amendments targeted Phase Two criteria for Navacaprant. 3. Investors affected if stock purchased after September 2023 qualify for claims. 4. Affected investors can seek lead plaintiff status until April 7, 2025.

4m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit raises concerns over trial data integrity and investor confidence. Similar biotech legal issues have led to immediate stock price declines in past cases.

How important is it?

The legal action poses a potential risk to NMRA's reputation and stock stability, prompting near-term volatility. Litigation involving clinical trial adjustments in biotech firms has historically impacted share prices significantly.

Why Short Term?

Legal news typically triggers swift market reactions, causing short-term volatility. Historically, class-action suit announcements produce immediate trading pressure until further developments.

Related Companies

NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=131760&wire=4 NMRA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora's flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. WHAT'S NEXT? If you suffered a loss in Neumora Therapeutics, Inc. during the relevant time frame, you have until April 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News